Research Article

Min Cheol Chang, Sang Gyu Kwak, Donghwi Park*

The effect of rTMS in the management of pain associated with CRPS

https://doi.org/10.1515/tnscl-2020-0120
received April 26, 2020; accepted September 09, 2020

Abstract

Background – Therapeutic management of pain in patients with complex regional pain syndrome (CRPS) is challenging. Repetitive transcranial magnetic stimulation (rTMS) has analgesic effects on several types of pain. However, its effect on CRPS has not been elucidated clearly. Therefore, we conducted a meta-analysis of the available clinical studies on rTMS treatment in patients with CRPS.

Materials and methods – A comprehensive literature search was conducted using the PubMed, EMBASE, Cochrane Library, and SCOPUS databases. We included studies published up to February 09, 2020, that fulfilled our inclusion and exclusion criteria. Data regarding measurement of pain using the visual analog scale before and after rTMS treatment were collected to perform the meta-analysis. The meta-analysis was performed using Comprehensive Meta-analysis Version 2.

Results – A total of three studies (one randomized controlled trial and two prospective observational studies) involving 41 patients were included in this meta-analysis. No significant reduction in pain was observed immediately after one rTMS treatment session or immediately after the entire schedule of rTMS treatment sessions (5 or 10 sessions; \( P > 0.05 \)). However, pain significantly reduced 1 week after the entire schedule of rTMS sessions (\( P < 0.001 \)).

Conclusion – rTMS appears to have a functional analgesic effect in patients with CRPS.

Keywords: complex regional pain syndrome, repetitive regional pain syndrome, pain, meta-analysis

1 Introduction

Complex regional pain syndrome (CRPS) is a chronic, painful condition that can affect any part of the body, but it commonly affects the limbs [1–6]. CRPS involves vasomotor changes such as changes in color and temperature of the skin, edema, increased sensitivity to touch, and a limited range of movement [1,2]. CRPS occurs due to any damage or injury to the central or peripheral nervous system and can also develop after direct trauma to the limbs [1,2]. CRPS is divided into two types – types I and II. CRPS type II is associated with a confirmed peripheral nerve injury, while CRPS type I is not associated with an obvious peripheral nerve injury [1,2].

The pain associated with CRPS is often severe and unresponsive to various treatment modalities, procedures, or oral administration of pharmacotherapeutic agents. Therefore, several patients with CRPS have severe, refractory pain that affects their quality of life and might result in unemployment [7,8]. In addition, the long-lasting, severe pain can result in psychological disorders such as depression and anxiety [9]. Therefore, controlling CRPS-induced pain is a challenge in clinical practice.

Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention, in which an electromagnetic coil is placed on the scalp to create a magnetic field [10–14]. The resulting magnetic stimulation changes the cortical excitability of the stimulation area and the distant areas transsynaptically. High-frequency (≥5 Hz) stimulation increases cortical excitability, while low-frequency (≤3 Hz) stimulation decreases the excitability [12]. Various types of chronic pain such as neuropathic pain, musculoskeletal pain, and fibromyalgia have been effectively controlled using rTMS [10,11,14,15]. Moreover, some studies have
reported a positive pain-controlling effect of rTMS in patients with CRPS \([16–21]\). However, since the aforementioned studies on rTMS are limited by their small sample size, the effect of rTMS on CRPS has not been clearly elucidated. However, previous review articles have reported that rTMS might be useful to alleviate pain in patients with CRPS \([19–21]\).

To evaluate the effectiveness of rTMS in controlling pain associated with CRPS, we conducted a meta-analysis of all available clinical studies involving rTMS treatment in patients with CRPS.

## 2 Methods

### 2.1 Search strategy

This meta-analysis was conducted in accordance with the preferred reporting items for systematic review and meta-analysis guidelines. The following databases were systematically searched for relevant studies published until February 09, 2020: PubMed, SCOPUS, EMBASE, and Cochrane Library. The key words used for the search were “(CRPS AND rTMS) OR (reflex sympathetic dystrophy AND rTMS).”

### 2.2 Eligibility criteria

Articles were included in this meta-analysis if they met the following criteria: (1) patients’ pain was induced by CRPS, (2) rTMS was used to manage the pain, (3) the pain levels were evaluated before and after rTMS treatment, and (4) studies involved human subjects. We included all studies published in English language, without any limitations on the study design such as randomized controlled trials (RCTs). Review articles, letters, or case reports and studies that reported inadequate data/results were excluded.

### 2.3 Study selection and data extraction

After the exclusion of duplicate publications, two independent reviewers (Donghwi Park [DP] and Min Cheol Chang [MCC]) evaluated the inclusion eligibility of potential articles. Articles were screened for eligibility

---

**Table 1: Characteristics of the included studies**

| Design                        | Included patients (n) | Disease duration (months) | rTMS mode | Outcome assessment time | Major adverse effect (N) |
|-------------------------------|-----------------------|---------------------------|-----------|-------------------------|--------------------------|
| Gaertner et al. (2018)        | 19                    | 64.8 ± 45.6               | 10 Hz, 80% RMT (10 Hz for 10 s with 30 s intertrain interval), a total of 2,600 pulses | Pre-rTMS, immediately after 1 session, immediately after 5 sessions, 1 week after finishing 5 sessions | 0 |
| Picarelli et al. (2010)       | 12                    | 80.8 ± 32.1               | 10 Hz, 100% RMT (10 Hz for 10 s with 30 s intertrain interval), a total of 2,500 pulses | Pre-rTMS, immediately after 1 session, immediately after 10 sessions, 1 week after finishing 10 sessions | 1 (generalized seizure) |
| Pleger et al. (2004)          | 10                    | 35 (range 24–72)          | 10 Hz, 100% RMT (a series of ten rTMS applications, each lasting 1.2 s in length), intertrain interval 10 s | Pre-rTMS, immediately after 1 session, immediately after 10 sessions, 1 week after finishing 10 sessions | 0 |
based on a review of the title and abstract, and disagreements were resolved by consensus. After the primary screening, the full texts of eligible articles were reviewed independently by two reviewers (DP and MCC). Subsequently, data on the first author, year of publication, sample size, demographic data, methods of rTMS, outcome measures (visual analog scale [VAS] scores), and major adverse effects were independently extracted from each eligible study (Table 1).

2.4 Quality assessment

The methodological quality of the studies was assessed using two different tools. The Cochrane Collaboration’s Handbook was used to determine adequate sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias in RCTs. Bias was categorized as “low risk,” “high risk,” or “unclear risk” [22]. The Newcastle–Ottawa scale (NOS) was used for assessing the quality of prospective observational studies based on three parameters—selection of subjects, comparability of groups, and assessment of outcome. The quality of each study was graded as low (score, 0–3), moderate (score, 4–6), and high (score, 7–9) [23]. All disagreements were resolved by consensus.

3 Statistical analysis

The extracted data were statistically analyzed using comprehensive meta-analysis version 2 (Biostat Inc.). For each analysis, a heterogeneity test was performed using I² statistic, which measures the extent of inconsistency among the results. When the P values were <0.05, the pooled data were considered having substantial heterogeneity, and the random-effects model was used for data analysis. When the P values were ≥0.05, the pooled data were considered homogeneous and the fixed-effects model was used for data analysis. Since the VAS scores are continuous variables, we analyzed the standardized mean difference (SMD) in the change from baseline and 95% confidence interval (CI). Subgroup analyses were performed according to the evaluation time points. The P values <0.05 were considered statistically significant.

4 Results

4.1 Study selection

The preliminary search of all the databases provided a total of 100 potentially relevant studies (Figure 1). After the elimination of duplicate studies, 66 articles were excluded based on the review of their titles and abstracts. The remaining studies were assessed by reviewing the full text of the articles. After a systematic review, three articles were included in the final analysis [16–18], which included one RCT [17] and two prospective observational studies [16,18]. Of the three studies, one was an open-label trial [16], one was a parallel study [17], and one was a crossover study. [18]

The data of patients who received rTMS treatment were extracted from the RCT conducted by Picarelli et al. [17]. Picarelli et al. [17] and Pleger et al. [18] administered rTMS treatment to patients with CRPS type I, and Gaertner et al. [16] administered rTMS treatment to patients with both CRPS types I and II.

4.2 Study characteristics

The selected studies included 49 cases. Pleger et al. [18] administered only one rTMS treatment session and evaluated its analgesic effect in 10 patients immediately after the session. Gaertner et al. [16] evaluated the analgesic effect of one rTMS treatment session in five patients and evaluated the change in the intensity of pain immediately and 1 week after five rTMS treatment sessions in 12 patients. Picarelli et al. [17] administered 10 rTMS treatment sessions in 22 patients and measured the intensity of pain immediately after the first rTMS session and immediately after the 10 sessions. Furthermore, follow-up evaluations were performed 1 week after the 10 rTMS treatment sessions.

4.3 Risk of bias

The study by Picarelli et al. was an RCT [17], and the risk of bias was assessed based on the Cochrane Handbook 5.1 Assessment Tool. The risk of bias for random sequence generation, allocation concealment, blinding of participants and personnel, and blinding of the outcome assessment was unclear. A low risk of bias
was observed for incomplete outcome data, selective reporting, and other biases. The other two observational studies were assessed using NOS [16,18]; Gaertner et al.’s study had a score of 12, which indicates a low risk of bias (selection of subjects: 4; comparability of groups: 4; and assessment of outcome: 4), and Pleger et al.’s study had a score of 6, which indicates a moderate risk of bias (selection of subjects: 2; comparability of groups: 1; and assessment of outcome: 3).

### 4.4 Results of the meta-analysis

We analyzed the effect of rTMS immediately after one rTMS treatment session and immediately after the entire schedule of rTMS treatment sessions (5 or 10 sessions). Additionally, the effect of rTMS was evaluated 1 week after the entire schedule of rTMS treatment sessions. Since the $P$ value for heterogeneity of the assessments that were performed immediately after one rTMS treatment session and immediately after the entire schedule of rTMS treatment sessions (5 and 10 sessions) was <0.05, the random-effects model was used (immediately after one rTMS session: $P = 0.002$, $I^2 = 84.114$, tau$^2 = 0.677$, $df = 2$; immediately after all rTMS sessions [5 and 10 sessions]: $P = 0.002$, $I^2 = 89.908$, tau$^2 = 3.792$, $df = 1$). The $P$ value for heterogeneity of the assessment 1 week after the entire schedule of rTMS treatment sessions was >0.05; hence, the fixed-effects model was used ($P = 0.088$, $I^2 = 65.676$, tau$^2 = 0.321$, $df = 1$; Figure 2).

An analysis of the VAS scores immediately after one rTMS treatment session and immediately after the entire schedule of rTMS treatment sessions (5 and 10 sessions) revealed no significant reduction in VAS scores (one rTMS session: SMD = −1.032, 95% CI = −2.067−0.003, $P = 0.051$; entire schedule of rTMS sessions: SMD = −2.368,
95% CI = −5.207–0.471, \( P = 0.102 \)). However, a tendency of reduction in pain was experienced by the study subjects. One week after the entire schedule of rTMS treatment sessions, the pain significantly reduced (SMD = −1.173, 95% CI = −1.709 to −0.637, \( P < 0.001 \)).

In the study by Gu and Chang [12], 1 of the 12 patients who received rTMS treatment developed generalized seizure. In the other two studies, no major adverse effects were reported.

### 4.5 Publication bias

A funnel plot analysis was performed for the assessment immediately after one rTMS treatment session. The graphical funnel plot, which involved the change in VAS scores reported by the studies included in this meta-analysis, appeared to be symmetrical (Figure 3). In addition, the publication bias was quantified using Egger's test. The intercept was found at −5.945
Therefore, a statistically significant publication bias was unlikely to occur.

5 Discussion

The current meta-analysis evaluated whether rTMS can alleviate pain associated with CRPS. A total of three studies were included and the pain scores, measured using the VAS, were analyzed. No significant reduction in pain was observed immediately after one rTMS treatment session. Similarly, no significant reduction in pain was observed immediately after 5 and 10 rTMS treatment sessions. A tendency toward decrease in pain was observed after one rTMS treatment session and after the completion of the entire schedule of rTMS treatment sessions (5 or 10 sessions). However, pain associated with CRPS was significantly reduced 1 week after the entire schedule of 5 or 10 rTMS treatment sessions. The effect size of the efficacy 1 week after 5 or 10 rTMS treatment sessions was −1.173. Based on Cohen’s study [24], this effect size value can be interpreted as follows: rTMS treatment has a large positive pain-reducing effect in patients with CRPS.

Hirayama et al. evaluated the analgesic effect of rTMS according to the areas stimulated [25]. They applied rTMS on the primary motor cortex, primary sensory cortex, premotor area, and supplementary motor area and observed that the primary motor cortex is the only target that can reduce pain. All the three studies included in the current meta-analysis stimulated the hand area of the primary motor cortex. The mechanism of action of rTMS that results in the reduction of pain has not been clearly elucidated. However, some possible mechanisms have been proposed. Previous studies that used functional magnetic resonance imaging have found that rTMS results in changes in the activity of cortical and subcortical areas associated with the processing of pain and modulation, such as the orbitofrontal cortex, anterior cingulate, medial thalamus, and periaqueductal gray matter [26,27]. The studies have suggested that rTMS can modify the hyperexcited pain-related areas, which triggers the cascade of analgesic synaptic events. rTMS is believed to trigger the descending inhibitory pathways to act at the dorsal horn level, which inhibits the conduction of pain signal to the brain [28]. Additionally, patients with chronic pain have a decreased blood flow [29]. rTMS increases the cerebral blood flow to the affected areas [29,30]. Moreover, rTMS might have antinociceptive effects by influencing the endogenous opioid system in the periaqueductal gray matter [31,32].

In our study, pain was not significantly reduced immediately after one rTMS treatment session or after 5 or 10 rTMS treatment sessions. However, significant reduction in pain was observed 1 week after 5 or 10 rTMS treatment sessions. The analgesic effect of rTMS was continuous and cumulative, even after the completion of rTMS therapy. To control pain associated with CRPS, the cumulative sustained effects of rTMS, which continue after the completion of therapy sessions, seem necessary.

In the study by Picarelli et al. [17], 1 of the 12 patients experienced a seizure during rTMS treatment. Seizure is one of the most serious adverse effects of rTMS therapy [33]. Although seizure occurs at a frequency of <0.1%, factors such as preexisting neurological conditions,
sleep deprivation, family history of seizures, and alcohol use can increase the risk of seizures [34].

In the current meta-analysis, we observed that rTMS therapy has the potential to control pain associated with CRPS. Since pain associated with CRPS is often refractory to various treatment methods, clinicians often find it challenging to treat patients with CRPS. Based on the results of this meta-analysis, we propose that rTMS can be a good treatment option for pain associated with CRPS. Furthermore, careful monitoring is warranted for adverse effects in patients with an increased risk of seizure.

The limitation of this study is that only three studies were included in the analysis. Therefore, subgroup analysis according to CRPS types I and II was not possible. However, to the best of our knowledge, this is the first meta-analysis evaluating the effects of rTMS on pain associated with CRPS. Further research is necessary to establish and explain the effect of rTMS in the management of pain associated with CRPS.

**Funding:** The present study was supported by a National Research Foundation of Korea grant funded by the Korean government (grant no. NRF-2019R1F1A1061348).

**Conflict of interest:** The authors state no conflict of interest.

**References**

[1] Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, et al. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for complex regional pain syndrome. Pain. 2010;150(2):268–74. Epub 2010/05/25. doi: 10.1016/j.pain.2010.04.030. PubMed PMID: 20493633; PubMed Central PMCID: PMCPMC2914601.

[2] Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med. 2007;8(4):326–31. Epub 2007/07/06. doi: 10.1111/j.1526-4637.2006.00169.x. PubMed PMID: 17610454.

[3] Park D. Recurrent complex regional pain syndrome type I in a patient with amyotrophic lateral sclerosis: a case report. Neurourol Urodyn. 2018;37(8):1487–8. Epub 2018/03/11. doi: 10.1002/nau.23305. PubMed PMID: 29524044.

[4] Lee BJ, Kim JY, Cho HJ, Park D. Sphingosine 1-phosphate receptor modulation attenuate mechanical allodynia in mouse model of chronic complex regional pain syndrome by suppressing pathogenic astrocyte activation. Reg Anesth Pain Med. 2020;45(3):230–8. Epub 2020/01/24. doi: 10.1136/rapm-2019-100801. PubMed PMID: 31969447.

[5] Lee SH, Lee JM, Kim YH, Choi JH, Jeon SH, Kim DK, et al. Antiallodynic Effects of Bee Venom in an Animal Model of Complex Regional Pain Syndrome Type 1 (CRPS-I). Toxins. 2017;9(9). Epub 2017/09/16. doi: 10.3390/toxins9090285. PubMed PMID: 28914784; PubMed Central PMCID: PMCPMC5618218.

[6] Kim JH, Park JS, Park D. Anti-allingenic effect of interleukin 10 in a mouse model of complex regional pain syndrome through reduction of NK1 receptor expression of microglia in the spinal cord. J Pain Res. 2018;11:1729–41. Epub 2018/09/21. doi: 10.2147/JPR.S166624. PubMed PMID: 30233230; PubMed Central PMCID: PMCPMC6129024.

[7] Mouraux D, Lenoir C, Tuna T, Brassinne E, Sobczak S. The long-term effect of complex regional pain syndrome type 1 on disability and quality of life after foot injury. Disabil Rehabil. 2019;1–9. Epub 2019/08/15. doi: 10.1080/09638288.2019.1650295. PubMed PMID: 3141910.

[8] Schwarm FP, Stein M, Uhl E, Maxeiner H, Kolodziej MA. Spinal cord stimulation for the treatment of complex regional pain syndrome leads to improvement of quality of life, reduction of pain and psychological distress: a retrospective case series with 24 months follow up. Scand J Pain. 2020;20(2):253–9. Epub 2019/11/20. doi: 10.1515/sjpain-2019-0081. PubMed PMID: 31743107.

[9] Brinkers M, Rumpelt P, Lux A, Kretzschmar M, Pfau G. Psychiatric disorders in complex regional pain syndrome (CRPS): the role of the consultation-Liaison psychiatrist. Pain Res Manag. 2018;2018:2894360. Epub 2018/11/13. doi: 10.1155/2018/2894360. PubMed PMID: 30416634; PubMed Central PMCID: PMCPMC6207853.

[10] Choi GS, Chang MC. Effects of high-frequency repetitive transcranial magnetic stimulation on reducing hemipelvic shoulder pain in patients with chronic stroke: a randomized controlled trial. Int J Neurosci. 2018;128(2):110–6. Epub 2017/08/15. doi: 10.1080/00207454.2017.1367682. PubMed PMID: 28805107.

[11] Choi GS, Kwak SG, Lee HD, Chang MC. Effect of high-frequency repetitive transcranial magnetic stimulation on chronic central pain after mild traumatic brain injury: a pilot study. J Rehabil Med. 2018;50(3):266–52. Epub 2018/02/03. doi: 10.2340/16501977-2321. PubMed PMID: 29392332.

[12] Gu SY, Chang MC. The effects of 10 Hz repetitive transcranial magnetic stimulation on depression in chronic stroke patients. Brain Stimul. 2017;10(2):270–4. Epub 2016/11/15. doi: 10.1016/j.brs.2016.10.010. PubMed PMID: 27893722.

[13] Chang MC, Choo YJ, Park D. The effect of repetitive transcranial magnetic stimulation on motor recovery can be different according to post-stroke periods. Am J Phys Med Rehabil. 2020. Epub 2020/08/01. doi: 10.1097/PHM.0000000000001538. PubMed PMID: 32732741.

[14] Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. Int J Rehabil Res. 2017;40(1):11–8. Epub 2016/12/16. doi: 10.1097/MRR.0000000000000207. PubMed PMID: 27977465.

[15] Lefaucheur JP, Nguyen JP. A practical algorithm for using rTMS to treat patients with chronic pain. Neurophysiol Clin. 2019;49(4):301–7. Epub 2019/08/04. doi: 10.1016/j.neucli.2019.07.016. PubMed PMID: 31375381.

[16] Gaertner M, Kong JT, Scherrer KH, Foote A, Mackey S, Johnson KA. Advancing transcranial magnetic stimulation methods for complex regional pain syndrome: an open-label study of paired theta burst and high-frequency stimulation.
Neurumodulation. 2018;21(4):409–16. Epub 2018/03/06. doi: 10.1111/ner.12760. PubMed PMID: 29504190; PubMed Central PMCID: PMCPMC6033652.

[17] Picarelli H, Teixeira MJ, de Andrade DC, Myczkowski ML, Luvisotto TB, Yeng LT, et al. Repetitive transcranial magnetic stimulation is efficacious as an add-on to pharmacological therapy in complex regional pain syndrome (CRPS) type I. J Pain. 2010;11(11):1203–10. Epub 2010/05/01. doi: 10.1016/j.jpain.2010.02.006. PubMed PMID: 20430702.

[18] Pleger B, Janssen S, Schwenkreis P, Volker B, Maier C, Tegenthoff M. Repetitive transcranial magnetic stimulation of the motor cortex attenuates pain perception in complex regional pain syndrome type I. Neurosci Lett. 2004;356(2):87–90. Epub 2004/01/30. doi: 10.1016/j.neulet.2003.11.037. PubMed PMID: 14746870.

[19] Nardone R, Brigo F, Heller Y, Sebastianelli L, Versace V, Saltuari L, et al. Transcranial magnetic stimulation studies in complex regional pain syndrome type I: a review. Acta Neurol Scand. 2018;137(2):158–64. Epub 2017/10/04. doi: 10.1111/an.12852. PubMed PMID: 28971481.

[20] Gallhardoni R, Correia GS, Araujo H, Yeng LT, Fernandes DT, Kaziyama HH, et al. Repetitive transcranial magnetic stimulation in chronic pain: a review of the literature. Arch Phys Med Rehabil. 2015;96(4 Suppl):S156–72. Epub 2014/12/02. doi: 10.1016/j.apmr.2014.11.010. PubMed PMID: 25437106.

[21] Yang S, Chang MC. Effect of repetitive transcranial magnetic stimulation on pain management: a systematic narrative review. Front Neurol. 2020;11:114. Epub 2020/03/07. doi: 10.3389/fneur.2020.00114. PubMed PMID: 32132973; PubMed Central PMCID: PMC7040236.

[22] Higgins JPGS. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. The Cochrane Collaboration. 2011.

[23] Institute, OHR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011.

[24] J. C. Statistical Power Analysis for the Behavioral Sciences. 1988.

[25] Hirayama A, Saitoh Y, Kishima H, Shimokawa T, Oshino S, Hirata M, et al. Reduction of intractable deafferentation pain by navigation-guided repetitive transcranial magnetic stimulation of the primary motor cortex. Pain. 2006;122(1–2):22–7. Epub 2006/02/24. doi: 10.1016/j.pain.2005.12.001. PubMed PMID: 16495011.

[26] Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review. Brain Res. 2004;1000(1–2):40–56. Epub 2004/04/01. doi: 10.1016/j.brainres.2003.10.073. PubMed PMID: 15053950.

[27] Uglem M, Omland PM, Engstrom M, Gravdahl GB, Linde M, Hagen K, et al. Non-invasive cortical modulation of experimental pain in migraine. Clin Neurophysiol. 2016;127(6):2362–9. Epub 2016/05/15. doi: 10.1016/j.clinph.2016.03.016. PubMed PMID: 27178854.

[28] Leung A, Donohue M, Xu R, Lee R, Lefaucheur JP, Khedr EM, et al. TMS for suppressing neuropathic pain: a meta-analysis. J Pain. 2009;10(12):1205–16. Epub 2009/05/26. doi: 10.1016/j.jpain.2009.03.010. PubMed PMID: 19464959.

[29] Garcia-Larrea L, Peyron R, Mertens P, Gregoire MC, Lavenne F, Le Bars D, et al. Electrical stimulation of motor cortex for pain control: a combined PET-scan and electrophysiological study. Pain. 1999;83(2):259–73. Epub 1999/10/27. doi: 10.1016/s0304-3959(99)00114-1. PubMed PMID: 10534598.

[30] Saitoh Y, Osaki Y, Nishimura H, Hirano S, Kato A, Hashikawa K, et al. Increased regional cerebral blood flow in the contralateral thalamus after successful motor cortex stimulation in a patient with poststroke pain. J Neurol Surg. 2004;100(5):935–9. Epub 2004/05/13. doi: 10.3171/jns.2004.100.5.0935. PubMed PMID: 15137612.

[31] de Andrade DC, Mhalla A, Adam F, Teixeira MJ, Bouhassira D. Neuropharmacological basis of rTMS-induced analgesia: the role of endogenous opioids. Pain. 2011;152(2):320–6. Epub 2010/12/15. doi: 10.1016/j.pain.2010.08.032. PubMed PMID: 21146300.

[32] Pagano RL, Fonoff ET, Dale CS, Ballester G, Teixeira MJ, Britto LR. Motor cortex stimulation inhibits thalamic sensory neurons and enhances activity of PAG neurons: possible pathways for antinoception. Pain. 2012;153(12):2359–69. Epub 2012/09/29. doi: 10.1016/j.pain.2012.08.002. PubMed PMID: 23017297.

[33] Lerner AJ, Wassermann EM, Tamir DI. Seizures from transcranial magnetic stimulation 2012–2016: results of a survey of active laboratories and clinics. Clin Neurophysiol. 2019;130(8):1409–16. Epub 2019/05/21. doi: 10.1016/j.clinph.2019.03.016. PubMed PMID: 31104898; PubMed Central PMCID: PMCPMC7274462.

[34] Dobek CE, Blumberger DM, Downar J, Daskalakis ZJ, Vila-Rodriguez F. Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion. Neuropsychiatr Dis Treat. 2015;11:2975–87. Epub 2015/12/15. doi: 10.2147/NDT.S91126. PubMed PMID: 26664122; PubMed Central PMCID: PMCPMC4670017.